Provided by Tiger Fintech (Singapore) Pte. Ltd.

bioAffinity Technologies, Inc.

0.3599
+0.114946.90%
Pre-market: 0.3243-0.0356-9.89%05:48 EDT
Volume:192.17M
Turnover:70.74M
Market Cap:9.91M
PE:-0.51
High:0.4600
Open:0.3585
Low:0.3002
Close:0.2450
Loading ...

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Business Wire
·
06 Mar

bioAffinity Technologies Raises $1.4 Million After Warrant Exercise

MT Newswires Live
·
27 Feb

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

PR Newswire
·
27 Feb

Press Release: WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Dow Jones
·
26 Feb

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Business Wire
·
25 Feb

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Zacks
·
06 Feb

The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity

Zacks
·
06 Feb

Top Research Reports for Amazon.com, Bank of America & Caterpillar

Zacks
·
06 Feb

BioAffinity Technologies Says Australian Patent Office Accepts Lung Cancer Test Application

MT Newswires Live
·
23 Jan

BRIEF-Bioaffinity Technologies Announces Acceptance Of Patent Application For Early-Stage Lung Cancer Diagnostic

Reuters
·
22 Jan

bioAffinity Technologies Inc - Australian Patent for Cypath Lung Test to Expire in 2042

THOMSON REUTERS
·
22 Jan

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

THOMSON REUTERS
·
22 Jan

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Business Wire
·
22 Jan